Reid Hospital & Health Care Services
- Type
- Teaching hospital
- Where
- Richmond, IN
- Medicare CCN
- 150048
- Received
- $691,904 in 128 records, 2019 ($6,597 general, $685,306 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: REID HOSPITAL AND HEALTH CARE SERVICES, INC. Fuzzy (name and state)
- Federal award recipient: REID HOSPITAL & HEALTH CARE SERVICES, INC. Fuzzy (name and state)
- Nonprofit: REID HOSPITAL & HEALTH CARE SERVICES INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 18 | $6,597 |
| 2019 | Research payment | 110 | $685,306 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Cardiovascular Systems Inc. | 15 | $625,910 | 2019 |
| Boehringer Ingelheim International GmbH | 87 | $29,095 | 2019 |
| Merck Sharp & Dohme LLC | 6 | $26,234 | 2019 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 2 | $4,066 | 2019 |
| Insulet Corporation | 2 | $3,600 | 2019 |
| Sterilmed, Inc. | 11 | $1,244 | 2019 |
| Hill-Rom Company, Inc | 2 | $1,217 | 2019 |
| Siemens Medical Solutions USA, Inc. | 1 | $332 | 2019 |
| Concordance Healthcare Solutions, LLC | 2 | $203 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 110 | $685,306 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 13 | $4,844 |
| Travel and Lodging | 1 | $1,034 |
| Food and Beverage | 3 | $385 |
| Charitable Contribution | 1 | $332 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $332 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-19 | Sterilmed, Inc. | $104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-19 | Concordance Healthcare Solutions, LLC | $11 | Food and Beverage (10 payments) | In-kind items and services | 2019 | ||
| 2019-12-11 | Insulet Corporation | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-12-03 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-11-21 | Cardiovascular Systems Inc. | $1,750 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-11-19 | Sterilmed, Inc. | $163 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-18 | Boehringer Ingelheim International GmbH | $1,056 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-10-30 | Cardiovascular Systems Inc. | $206,979 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-30 | Cardiovascular Systems Inc. | $918 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-23 | Sterilmed, Inc. | $122 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-15 | Boehringer Ingelheim International GmbH | $995 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-10-15 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-10-02 | Cardiovascular Systems Inc. | $875 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-02 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-06 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-06 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-06 | Boehringer Ingelheim International GmbH | $1,139 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-06 | Boehringer Ingelheim International GmbH | $398 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-06 | Boehringer Ingelheim International GmbH | $398 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-05 | Cardiovascular Systems Inc. | $1,225 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-09-05 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Sterilmed, Inc. | $101 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-04 | Boehringer Ingelheim International GmbH | $81 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $46 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $40 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $40 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $40 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-09-04 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-28 | Merck Sharp & Dohme LLC | $1,910 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-08-08 | Cardiovascular Systems Inc. | $918 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-08-07 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $51 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $51 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-02 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-08-01 | Sterilmed, Inc. | $105 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-31 | Merck Sharp & Dohme LLC | $12,920 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-07-31 | Merck Sharp & Dohme LLC | $2,364 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-07-25 | Cardiovascular Systems Inc. | $103,931 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-07-24 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-07-02 | Cardiovascular Systems Inc. | $875 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $80 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $80 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-07-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-06-26 | Sterilmed, Inc. | $120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-06-06 | Cardiovascular Systems Inc. | $568 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-05-29 | Sterilmed, Inc. | $108 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-16 | Boehringer Ingelheim International GmbH | $1,090 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-05-09 | Concordance Healthcare Solutions, LLC | $191 | Food and Beverage (18 payments) | In-kind items and services | 2019 | ||
| 2019-05-02 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-05-02 | Boehringer Ingelheim International GmbH | $995 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-05-02 | Cardiovascular Systems Inc. | $525 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-05-01 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-04-26 | Merck Sharp & Dohme LLC | $2,581 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-04-25 | Cardiovascular Systems Inc. | $176,302 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-04-25 | Sterilmed, Inc. | $82 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-04-04 | Cardiovascular Systems Inc. | $612 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-04-02 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-03-26 | Sterilmed, Inc. | $87 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-15 | Sterilmed, Inc. | $156 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-07 | Cardiovascular Systems Inc. | $918 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $135 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $81 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $81 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $73 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $72 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $66 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $42 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $21 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-01 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-03-01 | Boehringer Ingelheim International GmbH | $1,139 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,558 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | $508 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-25 | Merck Sharp & Dohme LLC | $1,243 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-02-25 | Boehringer Ingelheim International GmbH | $995 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-19 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-19 | Boehringer Ingelheim International GmbH | $1,410 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-19 | Boehringer Ingelheim International GmbH | $1,139 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-08 | Boehringer Ingelheim International GmbH | $6,000 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-08 | Boehringer Ingelheim International GmbH | $998 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-02-07 | Cardiovascular Systems Inc. | $128,722 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-02-01 | Cardiovascular Systems Inc. | $787 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $98 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $63 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $54 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $53 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-02-01 | Boehringer Ingelheim International GmbH | $21 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-31 | Hill-Rom Company, Inc | $1,034 | Travel and Lodging | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-01-31 | Hill-Rom Company, Inc | $182 | Food and Beverage | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-01-30 | Merck Sharp & Dohme LLC | $5,213 | Research payment | Cash or cash equivalent | MK-1242 Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2019 |
| 2019-01-24 | Sterilmed, Inc. | $92 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-01-04 | Boehringer Ingelheim International GmbH | $253 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $221 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $211 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $200 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $185 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $147 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $126 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $106 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $105 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $88 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $46 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $42 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $31 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-01-04 | Boehringer Ingelheim International GmbH | $21 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Richmond, IN, county Wayne County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Richmond, IN | County Wayne County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 35,581 | 66,397 | 6,851,073 |
| Population, 2020 census P1 | 35,720 | 66,553 | 6,785,528 |
| Median age B01002 | 38.6 | 41.0 | 38.1 |
| Under 18 B01001 | 22.4% | 22.6% | 23.3% |
| 65 and over B01001 | 18.9% | 19.7% | 16.8% |
| Households B11001 | 14,849 | 26,975 | 2,716,009 |
| Foreign born B05002 | 4.1% | 2.6% | 6.3% |
| Median household income B19013 | $45,399 | $55,692 | $71,957 |
| Median family income B19113 | $66,983 | $75,568 | $90,767 |
| Per capita income B19301 | $28,724 | $32,895 | $38,351 |
| Poverty rate B17001 | 25.4% | 17.9% | 12.3% |
| Unemployment rate B23025 | 6.9% | 5.4% | 4.3% |
| Civilian labor force B23025 | 15,776 | 31,085 | 3,472,016 |
| Mean commute (minutes) B08013 | 18.6 | 21.8 | 24.1 |
| Bachelor's degree or higher B15003 | 20.1% | 20.5% | 29.5% |
| Housing units B25001 | 17,312 | 30,736 | 2,976,568 |
| Owner-occupied B25003 | 57.2% | 69.2% | 70.6% |
| Renters B25003 | 42.8% | 30.8% | 29.4% |
| Median home value B25077 | $114,400 | $140,200 | $218,200 |
| Median gross rent B25064 | $822 | $815 | $1,062 |
| White, not Hispanic B03002 | 78.8% | 85.7% | 75.4% |
| Black B03002 | 6.2% | 3.8% | 9.1% |
| Hispanic or Latino B03002 | 5.4% | 4.0% | 8.6% |
| Asian B03002 | 1.5% | 0.9% | 2.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Richmond, IN.
Comments